Authors : Thiagasirpi Mani, Naveen Munusamy, Prema Anbarasu, Sri Harini Muruganandam, Harish Ponniah, Saravana Kumar Subramanian
DOI : 10.1111/ocr.70147
Volume : 29
Issue : 0
Year : 2026
Page No : 1-13
ABSTRACT This review aimed to investigate platelet‐rich plasma (PRP) and platelet‐rich fibrin (PRF) efficiency in reducing oronasal fistula during primary cleft lip and palate repair. An extensive search of PubMed, Google Scholar, Global Index Medics (WHO), PubMed Scopus, Cochrane Central, Proquest was performed up to march 2025. Eligible studies included prospective RCTs and non‐randomized controlled trials in human subjects. Patients aged 6–24 months undergoing primary cleft lip and palate repair were involved. Interventions involved intraoperative use of PRP/PRF compared with controls without PRP/PRF. The primary outcome was occurrence of oronasal fistula; secondary outcomes were scar width, wound infection and postoperative bleeding with wound dehiscence. Study selection followed PRISMA guidelines, and the risk of bias was determined with the ROB‐2 and ROBINS‐I method of assessment. Seven studies met the required criterion and were qualitatively synthesized. Evidence suggested that PRP/PRF application was associated with a lower incidence of oronasal fistula and reduced scar width compared with controls. Additional benefits included accelerated wound healing and faster recovery. The use of autologous PRP was also reported to decrease the need for further surgical interventions. However, the certainty of evidence was limited due to small sample sizes and methodological heterogeneity. PRP and PRF show promising benefits in cleft lip and palate repair, particularly decreased fistula formation and reduced scar width. Nevertheless, current evidence is of low to very low certainty. Larger, well‐designed randomized trials are required to validate the results obtained. Trial Registration: PROSPERO registration no. CRD420251032421